-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, S3DwIDiof6j4fGeCU2ezMlYJIPj0YcTLZ0gYKTpb7bbkwbfE/O3VY7qz+gib9f/f uY4v034cr8pYr84DwWbfZA== 0000950123-11-012870.txt : 20110211 0000950123-11-012870.hdr.sgml : 20110211 20110211170054 ACCESSION NUMBER: 0000950123-11-012870 CONFORMED SUBMISSION TYPE: SC 13G PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20110211 DATE AS OF CHANGE: 20110211 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: AVEO PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001325879 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G SEC ACT: 1934 Act SEC FILE NUMBER: 005-85745 FILM NUMBER: 11600197 BUSINESS ADDRESS: STREET 1: 75 SIDNEY STREET STREET 2: 4TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 6172995000 MAIL ADDRESS: STREET 1: 75 SIDNEY STREET STREET 2: 4TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02139 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: BIOGEN IDEC INC. CENTRAL INDEX KEY: 0000875045 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 330112644 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G BUSINESS ADDRESS: STREET 1: 133 BOSTON POST ROAD CITY: WESTON STATE: MA ZIP: 02493 BUSINESS PHONE: 7814642000 MAIL ADDRESS: STREET 1: 133 BOSTON POST ROAD CITY: WESTON STATE: MA ZIP: 02493 FORMER COMPANY: FORMER CONFORMED NAME: BIOGEN IDEC INC DATE OF NAME CHANGE: 20031112 FORMER COMPANY: FORMER CONFORMED NAME: IDEC PHARMACEUTICALS CORP / DE DATE OF NAME CHANGE: 19970530 SC 13G 1 b84854sc13g.htm AVEO PHARMACEUTICALS, INC. sc13g

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934
(Amendment No.            )*

Aveo Pharmaceuticals, Inc.
(Name of Issuer)
Common Stock
(Title of Class of Securities)
053588109
(CUSIP Number)
December 31, 2010
(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     o Rule 13d-1(b)

     o Rule 13d-1(c)

     þ Rule 13d-1(d)

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 
 

 

 

                     
CUSIP No.
  
053588109 
   Page  
2 
   of   
5 Pages 

 

           
1.   NAMES OF REPORTING PERSONS
Biogen Idec Inc.
     
     
2.   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
  (a)   o
  (b)   o
     
3.   SEC USE ONLY
   
   
     
4.   CITIZENSHIP OR PLACE OF ORGANIZATION
   
  Delaware (USA)
       
  5.   SOLE VOTING POWER
     
NUMBER OF   2,877,700
       
SHARES 6.   SHARED VOTING POWER
BENEFICIALLY    
OWNED BY  
       
EACH 7.   SOLE DISPOSITIVE POWER
REPORTING    
PERSON   2,877,700
       
WITH 8.   SHARED DISPOSITIVE POWER
     
   
     
9.   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
   
  2,877,700
     
10.   CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
   
  o
     
11.   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
   
  8.1%
     
12.   TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
   
  CO

 

 

                     
CUSIP No.
  
053588109 
   Page  
3 
   of   
5 Pages 
     
Item 1(a).
  Name of Issuer:
 
  Aveo Pharmaceuticals, Inc.
 
    
Item 1(b).
  Address of Issuer’s Principal Executive Offices:
 
  75 Sidney Street, Cambridge, MA 02139
 
    
Item 2(a).
  Name of Person Filing:
 
  Biogen Idec Inc.
 
    
Item 2(b).
  Address of Principal Business Office, or if None, Residence:
 
  133 Boston Post Road, Weston, MA 02493
 
    
Item 2(c).
  Citizenship:
 
  Delaware (USA)
 
    
Item 2(d).
  Title of Class of Securities:
 
  Common Stock
 
    
Item 2(e).
  CUSIP Number:
 
  053588109
 
Item 3.
  If this statement is filed pursuant to Sections 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
         
(a)
  o   Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o).
 
        
(b)
  o   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
 
        
(c)
  o   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
 
        
(d)
  o   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).
 
        
(e)
  o   An investment adviser in accordance with Section 240.13d-1(b)(1)(ii)(E);
 
        
(f)
  o   An employee benefit plan or endowment fund in accordance with Section 240.13d-1(b)(1)(ii)(F);
 
        
(g)
  o   A parent holding company or control person in accordance with Section 240.13d-1(b)(1)(ii)(G);
 
        
(h)
  o   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
 
        
(i)
  o   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
 
        
(j)
  o   A non-U.S. institution in accordance with Section 240.13d-1(b)(1)(ii)(J);
 
        
(k)
  o   Group, in accordance with Section 240.13d-1(b)(1)(ii)(K).
If filing as a non-U.S. institution in accordance with Section 240.13d-1(b)(1)(ii)(J), please specify the type of institution:__________

 

                     
CUSIP No.
  
053588109 
   Page  
4 
   of   
5 Pages 
     
Item 4.
  Ownership.
     Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
  (a)   Amount beneficially owned: 2,877,700
 
  (b)   Percent of class: 8.1%
 
  (c)   Number of shares as to which the person has:
  (i)   Sole power to vote or to direct the vote: 2,877,700
 
  (ii)   Shared power to vote or to direct the vote ___________________________,
 
  (iii)   Sole power to dispose or to direct the disposition of: 2,877,700
 
  (iv)   Shared power to dispose or to direct the disposition of ____________________________
     
Item 5.
  Ownership of 5 Percent or Less of a Class.
     If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following o.
     
Item 6.
  Ownership of More Than 5 Percent on Behalf of Another Person.
 
  Not applicable.
 
    
Item 7.
  Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
 
  Not applicable.
 
    
Item 8.
  Identification and Classification of Members of the Group.
 
  Not applicable.
 
    
Item 9.
  Notice of Dissolution of Group.
 
  Not applicable.
 
    
Item 10.
  Certifications.
 
  Not applicable.

 

                     
CUSIP No.
  
053588109 
   Page  
5 
   of   
5 Pages 
SIGNATURE
     After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
         
  Dated: February 11, 2011   
     
  /s/ Paul J. Clancy    
  Paul J. Clancy   
  Executive Vice President and Chief Financial Officer   
 

-----END PRIVACY-ENHANCED MESSAGE-----